TransMedics Group (NASDAQ:TMDX) Hits New 52-Week Low – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $55.00 and last traded at $56.73, with a volume of 2322802 shares. The stock had previously closed at $57.20.

Analysts Set New Price Targets

A number of research analysts recently commented on TMDX shares. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Finally, TD Cowen reduced their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 66.54 and a beta of 2.12. The firm has a 50 day moving average price of $69.56 and a 200-day moving average price of $115.95. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank raised its holdings in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC raised its stake in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after acquiring an additional 81 shares in the last quarter. Venturi Wealth Management LLC lifted its position in TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the last quarter. National Bank of Canada FI boosted its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Finally, Quarry LP boosted its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.